A new study of patients with colorectal cancer is challenging one of the most counterintuitive observations in cancer epidemiology: the so-called obesity paradox. In many analyses, people who are overweight or obese when diagnosed with cancer appear to survive longer than patients whose body mass index falls within the conventional “healthy” range. The finding has sometimes been misunderstood as suggesting that excess body weight might protect patients after diagnosis. The new research indicates that the apparent advantage is largely explained by a different process—unintentional weight loss caused by cancer before the disease is diagnosed.
Published in JAMA Network Open, the investigation used a case-control design combined with prospective follow-up of patients with colorectal cancer. Researchers examined body weight and body mass index around the time of diagnosis, then tracked patients’ outcomes over time. This approach allowed the team to study not only whether patients were classified as underweight, normal weight, overweight, or obese, but also how changes in weight before diagnosis may have influenced the relationship between BMI and survival.
The obesity paradox is particularly vulnerable to a statistical problem known as reverse causation. In ordinary studies, researchers may observe that a factor is associated with a later outcome and assume that the factor helped cause the outcome. In cancer research, however, the disease itself can alter the factor being measured. Colorectal tumors may reduce appetite, interfere with digestion or nutrient absorption, cause bleeding and inflammation, or increase the body’s energy requirements. Patients can therefore lose substantial weight before cancer is detected. If weight is measured only at diagnosis, these patients may be placed in a lower BMI category even though their earlier, prediagnostic weight was higher.
That distinction is crucial because cancer-associated weight loss is not simply a change in body size. It can reflect systemic biological processes known as cancer cachexia, a complex syndrome involving loss of muscle and fat, chronic inflammation, altered metabolism, reduced food intake, and changes in the way the body uses nutrients. Cachexia can weaken physical function and reduce tolerance to surgery, chemotherapy, radiotherapy, or other treatments. A patient who appears to have a “healthy” BMI at diagnosis may therefore be biologically more vulnerable than the BMI measurement alone suggests.
The researchers’ findings indicate that once prediagnostic weight loss was taken into account, much of the apparent survival advantage associated with overweight and obesity became less persuasive. The result does not mean that body weight is irrelevant to colorectal cancer. Long-term excess adiposity remains associated with an increased risk of developing several cancers, including colorectal cancer, and obesity can influence metabolic health, inflammation, treatment complications, and the likelihood of other chronic diseases. Rather, the study suggests that BMI at diagnosis is an incomplete and potentially misleading marker of a patient’s condition and prognosis.
BMI itself is a relatively blunt epidemiological tool. It is calculated by dividing weight in kilograms by height in meters squared, but it cannot distinguish muscle from fat, identify where fat is distributed, or reveal how recently a person’s weight has changed. Two patients with the same BMI may have very different levels of muscle mass, metabolic health, physical function, and disease-related weight loss. For cancer care, a history of weight change, nutritional status, muscle strength, inflammation, and treatment readiness may provide more clinically meaningful information than a single BMI value recorded at diagnosis.
The study also illustrates why observational cancer research must be interpreted with care. Researchers cannot randomly assign patients to different body weights, so analyses of BMI and survival can be affected by hidden differences between groups. Age, smoking, preexisting illness, treatment patterns, disease stage, physical activity, and socioeconomic conditions may all influence both body weight and survival. Statistical adjustment can reduce some of these distortions, but it cannot fully replace detailed information about a patient’s weight trajectory and the biological effects of the tumor. The case-control framework and prospective follow-up strengthen the analysis by linking prediagnostic characteristics to later outcomes, while still leaving the study observational rather than experimental.
For patients and clinicians, the practical message is not to pursue weight gain as a cancer treatment. The authors specifically caution that the apparent survival benefit associated with being overweight or obese at diagnosis should not be interpreted as evidence that people with a healthy weight should gain weight. Nor should the findings be used to overturn established survivorship recommendations. Weight management after treatment should remain individualized, taking into account nutritional needs, muscle preservation, physical activity, treatment effects, comorbidities, and the guidance of oncology and nutrition professionals.
The findings may help redirect future research toward a more dynamic view of body composition and cancer prognosis. Instead of relying on a single BMI measurement, studies could track weight change over time and combine it with imaging-based assessments of muscle and fat, laboratory markers of inflammation, dietary intake, physical performance, and treatment response. Such measures may clarify which patients are experiencing clinically important cachexia and which are simply being classified by a broad statistical category. They may also help clinicians identify nutritional decline earlier, when supportive interventions could be more effective.
The study, led by Marko Mandic, PhD, of the German Cancer Research Center in Heidelberg, Germany, reinforces a broader lesson in medical science: an apparently protective association can sometimes be the shadow cast by an unrecognized disease process. In colorectal cancer, a higher BMI at diagnosis may look favorable partly because illness has already driven some thinner patients into lower BMI categories. The observation is therefore less a reason to rethink the dangers of obesity than a warning to look beyond the number on the scale. Understanding what happened to a patient’s weight before diagnosis may be essential to understanding what that weight means after diagnosis.
Subject of Research: Colorectal cancer, body mass index, prediagnostic cancer-associated weight loss, obesity paradox, and survival
Web References: https://doi.org/10.1001/jamanetworkopen.2026.29571
Keywords: Colorectal cancer, obesity paradox, body mass index, weight loss, obesity, oncology, cancer cachexia, cancer survival, diagnosis, survivorship
